arrow
O

Oscar Krijgsman

agendia
H指数:34
被引数:5,563

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies

基于从诊断性肿瘤活检样本高通量TCR发现,实现下一代工程化TCR-T疗法

2025-01-140
OA
A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics

用于预测非小细胞肺癌对PD-1阻断无反应的功能失调的T细胞基因签名,适用于常规临床诊断

2023-12-134
OAAI
An adverse tumor-protective effect of IDO1 inhibition

IDO1抑制的不良肿瘤保护作用

2023-02-0110
OAAI
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
2022-04-0830
OAAI
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
2021-12-22151
OAAI
Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges
2021-12-2037
OA
High CD8+ tumour-infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapy

高CD8肿瘤浸润淋巴细胞密度与对新辅助放化疗反应不良的食管腺癌预后不良相关

2021-04-276
PREAI
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
2021-02-08218
PREAI
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade
2021-02-0237
OA
PERSONALIZED COMBINATION OF NEOADJUVANT DOMATINOSTAT, NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) IN MACROSCOPIC STAGE III MELANOMA PATIENTS STRATIFIED ACCORDING TO INTERFERON-GAMMA (IFN-GAMMA) SIGNATURE - THE DONIMI STUDY
2020-10-013
OAAI
36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials
2020-08-158
PRE
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
2020-08-0772
OAAI
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
2019-10-01228
OAAI
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
2019-06-0331
OAAI